

Alice Fabbri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1635276/publications.pdf>

Version: 2024-02-01

27
papers

717
citations

840776

11
h-index

552781

26
g-index

27
all docs

27
docs citations

27
times ranked

860
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Association Between Conflicts of Interest and Authors'™ Positions on Harms of Varenicline: a Cross-Sectional Analysis. <i>Journal of General Internal Medicine</i> , 2022, 37, 290-297. | 2.6 | 3 |
| 2 | “There are ways” drug companies will get into DTC decisions: How Australian drug and therapeutics committees address pharmaceutical industry influence. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2341-2353. | 2.4 | 5 |
| 3 | “Lines in the sand”™: an Australian qualitative study of patient group practices to promote independence from pharmaceutical industry funders. <i>BMJ Open</i> , 2021, 11, e045140. | 1.9 | 6 |
| 4 | Conflict of Interest Policies at Medical Schools and Teaching Hospitals: A Systematic Review of Cross-sectional Studies. <i>International Journal of Health Policy and Management</i> , 2021, , . | 0.9 | 6 |
| 5 | Global Media Coverage of the Benefits and Harms of Early Detection Tests. <i>JAMA Internal Medicine</i> , 2021, 181, 865. | 5.1 | 11 |
| 6 | Regulatory post-market drug safety advisories on cardiac harm: A comparison of four national regulatory agencies. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00680. | 2.4 | 2 |
| 7 | A descriptive analysis of medicines safety advisories issued by national medicines regulators in Australia, Canada, the United Kingdom and the United States 2007 to 2016. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1054-1063. | 1.9 | 9 |
| 8 | Mixed methods evaluation of workshops for citizen health advocates about financial conflicts of interests in healthcare. <i>BMJ Open</i> , 2020, 10, e034195. | 1.9 | 5 |
| 9 | Media coverage of drug regulatory agencies' safety advisories: A case study of citalopram and denosumab. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1416-1429. | 2.4 | 6 |
| 10 | Industry funding of patient and health consumer organisations: systematic review with meta-analysis. <i>BMJ</i> , 2020, 368, l6925. | 6.0 | 44 |
| 11 | Pharmaceutical industry payments to leaders of professional medical associations in Australia: Focus on cardiovascular disease and diabetes. , 2020, 49, 151-154. | | 11 |
| 12 | Association of food industry ties with findings of studies examining the effect of dairy food intake on cardiovascular disease and mortality: systematic review and meta-analysis. <i>BMJ Open</i> , 2020, 10, e039036. | 1.9 | 6 |
| 13 | How do health consumer organisations in Australia manage pharmaceutical industry sponsorship? A cross-sectional study. <i>Australian Health Review</i> , 2019, 43, 474. | 1.1 | 11 |
| 14 | Reply to the article: “What principles should guide interactions between population health researchers and the food industry? Systematic scoping review of peer-reviewed and grey literature”™. <i>Obesity Reviews</i> , 2019, 20, 1504-1506. | 6.5 | 1 |
| 15 | Medical donations are not always free: an assessment of compliance of medicine and medical device donations with World Health Organization guidelines (2009-2017). <i>International Health</i> , 2019, 11, 379-402. | 2.0 | 22 |
| 16 | Comparative Analysis of Medicines Safety Advisories Released by Australia, Canada, the United States, and the United Kingdom. <i>JAMA Internal Medicine</i> , 2019, 179, 982. | 5.1 | 21 |
| 17 | Secret safety warnings on medicines: A case study of information access requests. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 551-555. | 1.9 | 6 |
| 18 | Media Coverage of the Benefits and Harms of Testing the Healthy: a protocol for a descriptive study. <i>BMJ Open</i> , 2019, 9, e029532. | 1.9 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | “Asset exchange” interactions between patient groups and pharmaceutical industry: Australian qualitative study. <i>BMJ</i> , The, 2019, 367, l6694. | 6.0 | 18 |
| 20 | Pharmaceutical Industry Funding of Health Consumer Groups in Australia: A Cross-sectional Analysis. <i>International Journal of Health Services</i> , 2019, 49, 273-293. | 2.5 | 21 |
| 21 | Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and overactive bladder syndrome? An Australian cohort study. <i>BMJ Open</i> , 2018, 8, e019027. | 1.9 | 19 |
| 22 | The risk of bias in observational studies of exposures (ROBINS-E) tool: concerns arising from application to observational studies of exposures. <i>Systematic Reviews</i> , 2018, 7, 242. | 5.3 | 146 |
| 23 | The Influence of Industry Sponsorship on the Research Agenda: A Scoping Review. <i>American Journal of Public Health</i> , 2018, 108, e9-e16. | 2.7 | 177 |
| 24 | Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries. <i>International Journal of Health Policy and Management</i> , 2018, 7, 504-509. | 0.9 | 68 |
| 25 | Reporting bias in the literature on the associations of health-related behaviors and statins with cardiovascular disease and all-cause mortality. <i>PLoS Biology</i> , 2018, 16, e2005761. | 5.6 | 7 |
| 26 | The Inclusion of Nurses in Pharmaceutical Industry “Sponsored Events. <i>JAMA Internal Medicine</i> , 2016, 176, 1718. | 5.1 | 13 |
| 27 | Association of Industry Sponsorship With Outcomes of Nutrition Studies. <i>JAMA Internal Medicine</i> , 2016, 176, 1769. | 5.1 | 67 |